The online version of this article (doi:10.1186/s12865-017-0200-5) contains supplementary material, which is available to authorized users.
To assess the impact of disease activity on health-related quality of life (HRQoL) in systemic lupus erythematosus (SLE).
Cross-sectional study of patients included in the Swiss SLE Cohort Study between April 2007 and June 2014. HRQoL outcomes were based on the Medical Outcome Study Short Form 36 (SF-36). Disease activity was assessed by the SLE Disease Activity Index score with the Safety of Estrogens in SLE National Assessment modification (SELENA-SLEDAI) and by the physican’s global assessment (PGA).
Of the 252 patients included, 207 (82%) were women. Median [interquartile range (IQR)] age was 43 [32–57] years. SLE was active in 125 patients (49.6%). Median [IQR] mental component summary (MCS) in active vs inactive SLE was 40.0 [30.2–51.0] compared to 47.3 [39.2–52.8] (p < 0.01) and median [IQR] physical component summary (PCS) 43.7 [37.0–52.8] compared to 49.1 [38.4–55.6], respectively (p < 0.05). Increase in SELENA-SLEDAI or increase in PGA were negatively correlated with PCS and/or MCS. After adjusting for gender, age and disease duration, disease activity impacted on both PCS and MCS and all subscales except general health. Active lupus nephritis and musculoskeletal involvement were associated with physical limitations and emotional problems, increased bodily pain and poor social functioning. Low complement and/or presence of anti-dsDNA antibodies were associated with increased fatigue and reduced mental health.
In patients with SLE, HRQoL is reduced in those with active disease. Impact of disease activity on HRQoL dimensions depends on SELENA-SLEDAI system components.
Additional file 1: Table S1. Impact of disease activity by organ systems assessed through the SELENA-SLEDAI on health-related quality of life outcomes in 252 patients with systemic lupus erythematosus. (DOCX 96 kb)12865_2017_200_MOESM1_ESM.docx
Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384(9957):1878–88.
Ribi C, Trendelenburg M, Gayet-Ageron A, Cohen C, Dayer E, Eisenberger U, et al. The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Med Wkly. 2014;144:w13990. PubMed
Urowitz M, Gladman DD, Ibañez D, Sanchez-Guerrero J, Bae SC, Gordon C, et al. Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2014;66(9):1374–9. CrossRef
Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol. 2005;32(9):1706–8. PubMed
Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis. 2014;73(5):838–44. CrossRefPubMed
Devilliers H, Amoura Z, Besancenot J-F, Bonnotte B, Pasquali J-L, Wahl D, et al. Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology (Oxford). 2015;54(5):940–9.
Strand V, Petri M, Kalunian K, Gordon C, Wallace DJ, Hobbs K, et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford). 2014;53(3):502–11. CrossRef
Freire E, Bruscato A, Ciconelli R. Quality of life in systemic lupus erythematosus patients in Northeastern Brazil: Is health-related quality of life a predictor of survival for these patients? Acta Reumatol Port. 2009;34(2A):207–11. PubMed
Gladman DD, Urowitz MB, Ong A, Gough J, Mackinnon A. Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol. 1996;14(3):305–8. PubMed
Stoll T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol. 1997;24(8):1608–14. PubMed
Thumboo J, Fong KY, Ng TP, Leong KH, Feng PH, Thio ST, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol. 1999;26(1):97–102. PubMed
Gilboe IM, Kvien TK, Husby G. Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. J Rheumatol. 2001;28(2):266–74. PubMed
Chizzolini C, Cohen CD, Eisenberger U, Hauser T, Hunziker T, Leimgruber A, et al. Towards the Swiss systemic lupus erythematosus cohort study (SSCS). Rev Med Suisse. 2009;5(199):808–11. PubMed
Richard J-L, Bouzourène K, Gallant S, Ricciardi P, Sudre P, Iten A, et al. Validation et normes du SF-36 dans la population du canton de Vaud. Raisons de santé. 2000;28(1):1:61.
Vu TV, Escalante A. A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease. J Rheumatol. 1999;26(12):2595–601. PubMed
Mak A, Tay SH. Outcome of lupus glomerulonephritis: the role of prospective observational cohort studies. Rheumatology (Oxford). 2016;55(2):195–6. CrossRef
Hanly JG, Fisk JD, McCurdy G, Fougere L, Douglas J-A. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol. 2005;32(8):1459–6. PubMed
Gladman DD, Urowitz MB, Gough J, Mackinnon A. Fibromyalgia is a major contributor to quality of life in lupus. J Rheumatol. 1997;24(11):2145–8. PubMed
- Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)
Johannes von Kempis
for the Swiss Systemic Lupus Erythematosus Cohort Study Group
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II